Select Page

General Articles

Scientists inject one tumor and watch cancer vanish across the body

### Summary: Engineered CD40 Agonist Antibody Induces Systemic Tumor Regression in Phase 1 Trial A groundbreaking phase 1 clinical trial has demonstrated the potential of an engineered CD40 agonist antibody, 2141-V11, to elicit robust systemic anti-tumor responses with minimal toxicity. Developed by researchers at Rockefeller University, this modified antibody addresses longstanding limitations of traditional CD40…

Scientists found a surprising way to make exercise work better

### Summary: Ketogenic Diet Enhances Exercise Benefits in Hyperglycemic Models A recent study published in *Nature Communications* on February 25, led by exercise medicine researcher Sarah Lessard from the Fralin Biomedical Research Institute at Virginia Tech, explores how dietary interventions can augment the physiological benefits of exercise in individuals with hyperglycemia. Hyperglycemia, a hallmark of…

Just How Accurate Are Allergy Forecasts?

### Accuracy of Allergy Forecasts: Implications for Clinical Practice Allergy forecasts, commonly available on websites and apps, aim to help patients manage symptoms by predicting pollen levels, but their reliability is often questionable. Pollen counts, as reported by organizations like the National Allergy Bureau (NAB) under the American Academy of Allergy, Asthma & Immunology (AAAAI),…

Here’s What Doctors Should Know About the Stryker Cyberattack

### Summary: Key Implications of the Stryker Cyberattack for Clinical Practice In a recent cyberattack on Stryker Corporation, attributed to pro-Iran hackers and reported on March 11, 2026, the company’s internal Microsoft environment was compromised, leading to disruptions in order processing, manufacturing, and shipping. However, Stryker has confirmed that all medical products, including connected and…

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Your Title Goes Here